highlight the need for early intervention aimed to reduce risk factors for overweight or obesity in type 2 diabetic individuals to preserve their brain structure and cognitive function,” the authors wrote.
The blood glucose awareness training involved three 2.5-hour group sessions over 4 weeks plus 2 online modules to be done between group meetings.
Non-endocrinologist clinicians who electronically ordered glargine at a dose of 0.5 units/kg or greater incurred a warning screen, which advised either lowering the dose or contacting the diabetes consult service for approval.
These results clearly highlight the need to respect existing recommendations for dose reduction of sulphonylureas when initiating treatment with DPP-4 inhibitors, and the urgency to determine the efficacy of this
Incretin-based drugs not associated with higher risk of pancreatitis in large, population-based study
The findings of this study should provide some reassurance to patients treated with incretin-based drugs, according to the authors.
The differences among ethnic groups may be due to genetic, environmental, and behavioral factors, and highlight the need to identify ways to reduce disparities, they said.
Intense multifactorial intervention associated with increased life span, time to CVD events in type 2 diabetes
The intensive intervention was initially conducted for a median of 7.8 years and used both pharmacologic and behavioral methods to target coexisting risk factors for late complications of diabetes.
Elevations in high-sensitivity troponin T or N-terminal pro-B-type natriuretic peptide were significantly associated with risk of cardiovascular death, myocardial infarction, and hospitalization for heart failure, while C-reactive protein was a less
Patients with type 2 diabetes and a systolic blood pressure of 110 to 119 mm Hg appeared to have a lower risk of cardiovascular disease than patients who had systolic blood pressures of 130 to 139 mm Hg, according to a registry study.
Despite increasing adoption of insulin pumps and continuous glucose monitors, control of HbA1c hasn't necessarily improved, the authors noted.